[go: up one dir, main page]
Ipilimumab

"Ipilimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Definition   |   Details   |   More General Concepts   |   Related Concepts   |   More Specific Concepts
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.


expand / collapse Publications
This graph shows the total number of publications written about "Ipilimumab" by people in this website by year, and whether "Ipilimumab" was a major or minor topic of these publications.
Below are the most recent publications written about "Ipilimumab" by people in Profiles.
  1. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):830-837.
    View in: PubMed
  2. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):308-315.
    View in: PubMed
  3. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600.
    View in: PubMed
  4. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28; 391(21):2014-2026.
    View in: PubMed
  5. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. J Clin Oncol. 2025 Jan 10; 43(2):189-200.
    View in: PubMed
  6. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Dec; 35(12):1191-1199.
    View in: PubMed
  7. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro Oncol. 2024 09 05; 26(9):1628-1637.
    View in: PubMed
  8. Reply to the Letter to the Editor "Reflections on the statistical methodology in nivolumab and ipilimumab therapy research" by S. Yang. Ann Oncol. 2024 Sep; 35(9):827-828.
    View in: PubMed
  9. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med. 2024 Oct 07; 221(10).
    View in: PubMed
  10. Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors. Hepatol Commun. 2024 09 01; 8(9).
    View in: PubMed
People
People who have written about this concept.
Explore @UCSF
_
Similar Concepts expand description
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.

UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03.

Copyright © The Regents of the University of California.